CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo

Tumor Biology

Volumn 36, Issue 3, 2015, Pages 1437-1444

  He, Xingxing ^a   Kong, Xinjuan ^b   Yan, Junwei ^a   Yan, Jingjun ^a   Zhang, Yunan ^a   Wu, Qian ^a   Chang, Ying ^a   Shang, Haitao ^a   Dou, Qian ^b   Song, Yuhu ^a   Liu, Fang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; Cell cycle; Colorectal cancer; CP 31398; Mutant p53

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; CASPASE 3; CYCLIN D; MDM2 PROTEIN, HUMAN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; PYRIMIDINE DERIVATIVE; TP53 PROTEIN, HUMAN;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENETICS; HT 29 CELL LINE; HUMAN; MOUSE; NUDE MOUSE; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLIN D; HT29 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; PYRIMIDINES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930891710     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2389-8     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479–507.
3. Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009;137:609–22.
4. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2:a001107.
5. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol. 2011;223:116–26.
6. Muller PA, Vousden KH. P53 mutations in cancer. Nat Cell Biol. 2013;15:2–8.
7. Lozano G. Mouse models of p53 functions. Cold Spring Harb Perspect Biol. 2010;2:a001115.
8. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26:1268–86.
9. Lane DP, Cheok CF, Lain S. P53-based cancer therapy. Cold Spring Harb Perspect Biol. 2010;2:a001222.
10. Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol. 2011;2011:978312.
11. Lehmann BD, Pietenpol JA. Targeting mutant p53 in human tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:3648–50.
12. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov. 2008;7:979–87.
13. Rao CV, Swamy MV, Patlolla JM, Kopelovich L. Suppression of familial adenomatous polyposis by cp-31398, a tp53 modulator, in apcmin/+mice. Cancer Res. 2008;68:7670–5.
14. Rao CV, Steele VE, Swamy MV, Patlolla JM, Guruswamy S, Kopelovich L. Inhibition of azoxymethane-induced colorectal cancer by cp-31398, a tp53 modulator, alone or in combination with low doses of celecoxib in male f344 rats. Cancer Res. 2009;69:8175–82.
15. Wang Z, Liu F, Tu W, Chang Y, Yao J, Wu W, et al. Embryonic liver fodrin involved in hepatic stellate cell activation and formation of regenerative nodule in liver cirrhosis. J Cell Mol Med. 2012;16:118–28.
16. Wang Z, Song Y, Tu W, He X, Lin J, Liu F. Beta-2 spectrin is involved in hepatocyte proliferation through the interaction of tgfbeta/smad and pi3k/akt signalling. Liver Int Off J Int Assoc Study Liver. 2012;32:1103–11.
17. He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, et al. Microrna-375 targets aeg-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31:3357–69.
18. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2:594–604.
19. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst. 1994;86:1458–62.
20. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996;2:985–91.
21. Guo J, Xin H. Chinese gene therapy splicing out the west? Science. 2006;314:1232–5.
22. North S, El-Ghissassi F, Pluquet O, Verhaegh G, Hainaut P. The cytoprotective aminothiol wr1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene. 2000;19:1206–14.
23. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002;8:282–8.
24. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A. 2002;99:937–42.
25. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR. Characterization of the p53-rescue drug cp-31398 in vitro and in living cells. Oncogene. 2002;21:2119–29.
26. Peng Y, Li C, Chen L, Sebti S, Chen J. Rescue of mutant p53 transcription function by ellipticine. Oncogene. 2003;22:4478–87.
27. Demma MJ, Wong S, Maxwell E, Dasmahapatra B. Cp-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J Biol Chem. 2004;279:45887–96.
28. Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR, et al. Cp-31398 restores mutant p53 tumor suppressor function and inhibits uvb-induced skin carcinogenesis in mice. J Clin Invest. 2007;117:3753–64.
29. Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H, et al. Targeting wild-type and mutant p53 with small molecule cp-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res. 2010;70:6566–76.
30. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science. 1999;286:2507–10.
31. Wang W, Takimoto R, Rastinejad F, El-Deiry WS. Stabilization of p53 by cp-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or mdm2 binding. Mol Cell Biol. 2003;23:2171–81.
32. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS. The mutant p53-conformation modifying drug, cp-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther. 2002;1:47–55.
33. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. P53 mutations in colorectal cancer. Proc Natl Acad Sci U S A. 1990;87:7555–9.
34. Liu Y, Bodmer WF. Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci U S A. 2006;103:976–81.